914299-79-9

Basic information

• Product Name: (S)-3-phenylmorpholine
• Synonyms: (S)-3-phenylmorpholine;Morpholine, 3-phenyl-, (3S)-;(3S)-3-phenylmorpholine
• CAS NO: 914299-79-9
• Molecular Formula: C₁₀H₁₃NO
• Molecular Weight: 163.2
• Mol File: 914299-79-9.mol

Chemical Properties

• Boiling Point: 272°C at 760 mmHg
• Flash Point: 104.9°C
• Appearance: /
• Density: 1.034g/cm³
• Vapor Pressure: 0.00623mmHg at 25°C
• Refractive Index: 1.518
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: (S)-3-phenylmorpholine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-phenylmorpholine(914299-79-9)
• EPA Substance Registry System: (S)-3-phenylmorpholine(914299-79-9)

Safety Data

• Hazardous Substances Data: 914299-79-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-3-phenylmorpholine is used as a building block for the synthesis of various bioactive compounds and pharmaceutical drugs. Its unique structure and properties contribute to the development of new and effective medications.
Used in Asymmetric Catalysis:
(S)-3-phenylmorpholine is used as a chiral ligand in asymmetric catalysis, a technique that allows for the selective synthesis of enantiomers, which are crucial in the production of chiral drugs with specific biological activities. This application enhances the efficiency and selectivity of chemical reactions, leading to the production of desired enantiomers with improved purity and yield.

InChI:InChI=1/C10H13NO/c1-2-4-9(5-3-1)10-8-12-7-6-11-10/h1-5,10-11H,6-8H2/t10-/m1/s1

Upstream product

• 529-20-4 2-methylphenyl aldehyde 
• 20989-17-7 (2S)-2-phenylglycinol 
• 79-04-9 chloroacetyl chloride 
• 1544430-88-7 (3S)-3-phenyl-4-(para-toluenesulfonyl)morpholine 
• 108-95-2 phenol 
• 291545-74-9 (S)-2-chloro-N-(2-hydroxyl-1-phenylethyl)acetamide 
• 1052209-96-7 (S)-5-phenylmorpholin-3-one 

Downstream Products

• 1052208-78-2 C₁₉H₂₂N₂O₂S 
• 1544431-59-5 (3S)-3-phenyl-N-methylmorpholine 

Relevant articles and documents

Using the competing enantioselective conversion method to assign the absolute configuration of cyclic amines with BODE’s acylation reagents

The competing enantioselective conversion (CEC) method is a quick and reliable means to determine absolute configuration. Previously, Bode’s chiral acylated hydroxamic acids were used to determine the stereochemistry of primary amines, as well as cyclic and acyclic secondary amines. The enantioselective acylation has been evaluated for 4-, 5-, and 6-membered cyclic secondary amines, including medicinally relevant compounds. The limitations of the method were studied through computational analysis and experimental results. Piperidines with substituents at the 2-position did not behave well unless the axial conformer was energetically accessible, which is consistent with the transition state geometries proposed by Bode and Kozlowski. Control experiments were performed to investigate the cause of degrading selectivity under the CEC reaction conditions. The present study expands the scope of the CEC method for secondary amines and provides a better understanding of the reaction profile.

SUBSTITUTED MORPHOLINE DERIVATIVES AS ROR GAMMA MODULATORS

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, X1, X2, m and n are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORyt). These compounds prevent, inhibit, or suppress the action of RORyt and are therefore useful in the treatment of RORyt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer. (I)

Aminoheteroaryl benzamides as kinase inhibitors

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

Catalytic Synthesis of N-Unprotected Piperazines, Morpholines, and Thiomorpholines from Aldehydes and SnAP Reagents

Commercially available SnAP (stannyl amine protocol) reagents allow the transformation of aldehydes and ketones into a variety of N-unprotected heterocycles. By identifying new ligands and reaction conditions, a robust catalytic variant that expands the substrate scope to previously inaccessible heteroaromatic substrates and new substitution patterns was realized. It also establishes the basis for a catalytic enantioselective process through the use of chiral ligands. SnAPcat! The identification of new ligands and reaction conditions provides a robust catalytic method for the synthesis of N-unprotected heterocycles using SnAP reagents. This catalytic variant expands the substrate scope to include previously inaccessible piperazines, morpholines, and thiomorpholines and establishes the basis for a catalytic enantioselective process through the use of chiral ligands.

Tertiary amine-promoted enone aziridination: Investigations into factors influencing enantioselective induction

trans-N-Unsubstituted aziridines were synthesised (up to 77% ee) via a chiral tertiary amine-promoted nucleophilic aziridination of a,b-unsaturated ketones utilising in situ generated N-N ylides (aminimines). A wide range of chiral tertiary amines were sy

Amine-promoted asymmetric (4+2) annulations for the enantioselective synthesis of tetrahydropyridines: A traceless and recoverable auxiliary strategy

Gone, without a trace: The in situ reaction of 2-(acetoxymethyl)buta-2,3- dienoate and a secondary amine produces a 2-methylene-3-oxobutanoate equivalent that can be used in asymmetric [4+2] annulations with N-tosylimines to provide tetrahydropyridines in

4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase

4-(1,3-Thiazol-2-yl)morpholine derivatives have been identified as potent and selective inhibitors of phosphoinositide 3-kinase. The SAR data of selected examples are presented and the in vivo profiling of compound 18 is shown to demonstrate the utility of this class of compounds in xenograft models of tumor growth.